Citigroup Inc. has announced a new offering of unsecured debt securities through a preliminary pricing supplement filed with the SEC. This move signals the company's continued commitment to providing innovative financial products to its investors and clients.
Citigroup, a major player in the national commercial banking sector, operates under the ticker symbols C, C-PN, and C-PR on the New York Stock Exchange. The company has a long history of adapting to market demands, as evidenced by its recent filings, including several 424B2 forms submitted on October 26, 2026, which indicate ongoing activity in the capital markets.
The recent SEC filing, accession number 0001918704-26-032197, details the offering of medium-term senior notes linked to Boston Scientific Corporation. These securities are designed to offer investors the potential for periodic contingent coupon payments, which could yield higher returns compared to conventional debt securities of similar maturity. However, the filing also highlights the risks involved, including the potential for lower yields and the possibility of receiving significantly less than the stated principal amount at maturity.
Investors in these securities should be aware of the credit risks associated with both Citigroup Global Markets Holdings Inc. and Citigroup Inc., as all payments on the securities are guaranteed by Citigroup Inc. The offering is structured to provide a contingent coupon payment of 0.8667% of the stated principal amount, contingent upon the performance of the underlying asset.
This new offering may attract a range of investors, including institutional and retail investors looking for higher yield opportunities in a low-interest-rate environment. The securities are not listed on any exchange, which may limit liquidity for some investors.
Looking ahead, Citigroup may provide further details or updates regarding this offering in subsequent filings, but the current filing does not specify the next steps in the process.